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SUMMARY
Polycystic liver disease (PLD) is a rare genetic disorder with progressive
cyst growth as the primary phenotype. Therapy consists of volume reduc-
tion through invasive surgical or radiological procedures. To understand
the process of treatment decision, our aim was to identify factors that
increased the likelihood of treatment. We performed a cross-sectional
study using an international population of patients with PLD. We collected
data on the following therapies: liver transplantation, resection, fenestra-
tion, and aspiration sclerotherapy. Data on the potential determinants, sex,
center, autosomal dominant polycystic kidney disease (ADPKD), autoso-
mal dominant polycystic liver disease (ADPLD), age at diagnosis, symp-
toms, and phenotype, were included. We corrected for follow-up time. We
included 578 patients in our study, and 35% underwent invasive therapy.
Multivariate regression analysis showed that number of symptoms and age
at diagnosis of PLD increased the likelihood of treatment (respectively, RR:
1.4, P < 0.001 and RR = 1.4, P = 0.03). The choice for liver transplanta-
tion or aspiration sclerotherapy was center dependent (RR: 0.7, P < 0.001
and RR: 1.1, P = 0.03, respectively). The results of our international cross-
sectional study suggest that a higher number of symptoms and every
10 years of PLD diagnosis increase the risk to undergo treatment by 40%.
The choice to elect a particular modality is center dependent.
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Introduction
Polycystic liver disease (PLD) is a condition character-
ized by progressive liver cyst growth [1]. PLD is part of
the phenotype of two genetically distinct disorders. It is
presented as a primary phenotype in autosomal domi-
nant polycystic liver disease (ADPLD), and it is the
most common extra-renal manifestation in autosomal
dominant polycystic kidney disease (ADPKD) [2–4].
Isolated PLD is rare with a prevalence of 1 in 158 000,
which contrasts that of ADPKD which has a higher
prevalence (1:400–1000 individuals) [5,6]. The vast
majority of patients with ADPKD (94%) >35 years of
age possess hepatic cysts [4].
Although PLD is often asymptomatic, patients who
progress to severe hepatomegaly have a decreased
health-related quality of life and are often in need of
therapy [7,8]. Risk factors for progressive disease are
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age, female sex, estrogen use, and pregnancies
[4,8–10]. The concept central to PLD therapy is down-
sizing liver volume as this leads to improvement of
symptoms [3]. Currently, the mainstay of therapies
includes invasive surgical and radiological procedures
such as, liver transplantation, the only curative treat-
ment, resection, fenestration, and aspiration sclerother-
apy [2,11]. Treatment is indicated in patients who
suffer from symptomatic hepatomegaly, and the choice
for a specific therapy mainly depends on the presence
and location of dominant cysts [2,3,12]. Clear guideli-
nes about timing and choice of therapy are lacking.
This might be explained by a lack of evidence gener-
ated by clinical trials comparing efficacy of invasive
treatment strategies for PLD. In addition, there are no
standardized outcome measures to assess treatment
success in clinical practice, which hampers the building
of an evidence base.
To guide physicians on therapy, it is necessary to
explore factors involved in the process of treatment
decision. To this end, we aimed to delineate patient
characteristics and disease-specific factors that trigger
therapy. Our secondary aim was to identify determi-
nants that increased the likelihood of a specific invasive
therapy for PLD.
Materials and methods
Study design and subjects
We performed a cross-sectional study that included
patients with PLD coming from two independent PLD
registries. Both registries were developed at two nation-
wide referral hospitals for PLD, Radboud University
Medical Center Nijmegen in the Netherlands (center 1)
and University Hospital of Leuven in Belgium (center
2) [13]. Both hospitals are national referral centers for
clinical evaluation and treatment of PLD. The Dutch
registry contains all patients with PLD who have visited
the outpatient clinic of the Department of Hepatology
of the Radboud University Medical Center between Jan-
uary 2008 and February 2015. Patients with ADPKD
who had visited the Department of Nephrology between
January 2008 and December 2014 were included, if PLD
was present. The Belgium registry includes all patients
with PLD who had visited the outpatient clinic of the
Department of Hepatology of the University Hospital of
Leuven, from January 2008 to July 2015. According to
the Dutch and Belgium regulations, these registries do
not need formal ethical approval as this was an observa-
tional study.
The inclusion criterium for this analysis was a diag-
nosis of PLD as documented by patients’ physician
where diagnosis of PLD had literally to be written down
in the medical file of patients, or as shown on radiologi-
cal imaging by the presence of ≥20 hepatic cyst larger
than 0.5 cm. Underlying diagnosis of ADPKD or
ADPLD was a requirement. ADPKD diagnosis was
based upon modified Ravine criteria [14], and ADPLD
diagnosis was based on the presence of ≥20 liver cysts,
in the absence of renal cysts. If renal cysts were present
in patients with ADPLD, the Ravine criteria should not
be met [15]. Patients with hepatic cysts due to other
diseases (e.g., Caroli’s disease, autosomal resistant poly-
cystic kidney disease) were excluded.
Potential determinants for treatment
We selected the following patient characteristics and
disease-specific factors as potential determinants for
treatment: sex, age at PLD diagnosis, phenotype, under-
lying diagnosis of PLD (ADPKD or ADPLD), number
of symptoms, total liver volume (TLV), height-adjusted
TLV (hTLV), estrogen use, and history of pregnancy.
Center was also added as a factor determining choice of
treatment. Parameters that pertained treatment decision
were chosen on the basis of expert opinion, and evi-
dence coming from studies on risk factors for severe
PLD [4,5,9,10].
Data collection
Data were retrospectively collected from medical charts
of patients. We included information on the following
invasive treatment modalities: liver transplantation
(combined with or without renal transplantation),
resection, fenestration, and aspiration sclerotherapy.
Experimental therapies such as somatostatin analogues
were excluded as these drugs are mainly used in clinical
trial settings. We reviewed medical charts for demo-
graphics, underlying diagnosis of PLD, age at diagnosis
of PLD, TLV, hTLV, estrogen use, and pregnancies. We
used the most recent value for TLV that was available.
Liver volumes had been calculated in the past by 3D
measurements of CT scans. This included manually out-
lining of the liver every 9 mm with interpolation of
intermediate slices and calculation of TLV. We also col-
lected data on hepatic cyst phenotype by assessing MRI,
CT, ultrasound images, or reviewing imaging reports.
We have distinguished between a phenotype with either
the presence or absence of one or more dominant cysts
(≥8 cm). Finally, we collected data on the presence of
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the following symptoms in medical records of patients:
abdominal discomfort, feeling full, abdominal pain,
tiredness, pain in the rib cage, and pain in the side.
These symptoms were selected as they were overrepre-
sented in a Dutch population of patients with symp-
tomatic PLD [16].
Statistical analysis
We performed descriptive statistical analyses to summa-
rize population characteristics. Baseline continuous vari-
ables were expressed in mean [standard deviation (SD)]
for normally distributed data or median [interquartile
range (IQR)] for non-normally distributed data.
Dichotomous outcomes were expressed as % (n/n
total).
For our primary and secondary aims, we used multi-
variate logarithmic linked modified Poisson regression
analysis to generate risk ratios (RRs) for determinants
associated with, respectively, treatment and specific
treatment modalities [17,18]. Risk ratios >1 and <1
were interpreted as, respectively, increasing and decreas-
ing the likelihood of treatment or a specific therapy,
while a risk ratio equal to 1 with a 95% CI smaller than
1 indicates no association. We included a potential
determinant in the regression model only if at least 10
patients (1.7% of 578 patients) were exposed to the
determinant to guarantee adequate statistical power. For
the primary analysis, the dependent variable was speci-
fied as treatment or no treatment, whereas treatment
was defined as patients who underwent surgical or radi-
ological therapy, at least once. Independent variables
included sex, center, age at diagnosis of PLD (defined as
age at diagnosis of PLD divided by 10 years), pheno-
type, underlying diagnosis (ADPKD or ADPLD), num-
ber of symptoms, TLV, hTLV, estrogen use, and
pregnancy in history. We added the variable follow-up,
defined as interval from diagnosis to inclusion in the
study divided by 10 years to the model to correct for
follow-up period.
For our secondary analysis, liver transplantation,
resection, fenestration, and aspiration sclerotherapy
were included as dependent variables. In this analysis,
the same independent variables as for the primary
analysis were included. Unpaired Student’s t-test or
chi-square test was used to compare patient character-
istics or disease characteristics between specific treat-
ment modalities. In addition, a subgroup analysis of
hepatic phenotype and treatment strategy between
patients with ADPKD and ADPLD was performed.
Finally, we tested whether patients who underwent
aspiration sclerotherapy or fenestration differed on sex,
center, age at diagnosis of PLD, phenotype, and under-
lying diagnosis of PLD. If patients underwent aspira-
tion sclerotherapy and fenestration, the first treatment
that was given was used for this analysis. A P-value of
<0.05 was considered statistical significant. Data were
analyzed using SPSS 22.0 (SPSS Statistics Inc., Chicago,
IL, USA).
Results
Characterization of the study population
We included 578 patients in our study population, and
200 (35%) underwent invasive therapy (Fig. 1). The
large majority of patients were female (81%) and 383
(66%) had an underlying diagnosis of ADPKD
(Table 1). A total of 421 patients showed a phenotype
without dominant cysts while a phenotype with con-
comitant dominant cysts was present in 54 patients.
Liver phenotype significantly differed between patients
with ADPKD and ADPLD (Fig. 2). Patients with
ADPLD possessed dominant cysts on radiological
Transplantation
(n = 77, 13%)
Aspiration
sclerotherapy
(n = 100, 17%)
Fenestration
(n = 48, 8%)
Resection
(n = 6, 1%)
Treated
(n = 200, 35%)
Untreated
(n = 378, 65%)
Included in registry
(n = 578)
Figure 1 Overview of the study
population. A total of 578 patients
were included, and 35% (n = 200)
received therapy. A number of
patients received ≥1 treatment
modality.
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imaging in 34 patients (22%) whereas this was the case
in only 21 of patients with ADPKD (7%) (P < 0.001).
Most patients were Dutch (66%, n = 380), and strati-
fication of patients by center demonstrated that popula-
tions from both centers were comparable with respect
to sex, TLV, and hTLV (Table S1). Dutch patients had
more symptoms, were more often diagnosed with
ADPLD, were diagnosed at a later age, and more often
possessed a phenotype without dominant cysts. The fol-
low-up of patients at the University Hospital of Leuven
in Belgium was significantly longer than the follow-up
of patients at the Radboudumc in the Netherlands (18
vs. 7 years, P < 0.001). Therefore, all analysis was cor-
rected for follow-up time by including this in the multi-
variate model.
Determinants that trigger treatment
Liver transplantation, resection, fenestration, and aspira-
tion sclerotherapy were performed in, respectively, 13%,
1%, 8%, and 17% of patients (Fig. 1). Multivariate
regression analysis revealed that patients who suffer from
more symptoms have a 40% higher likelihood (CI: 1.17–
1.60, P < 0.001) to receive treatment (Fig. 3, Table S2.).
Every 10 years of diagnosis of PLD was also significantly
associated with a 40% increased risk of treatment (CI:
1.04–1.88, P = 0.03). TLV, hTLV, estrogen use, and preg-
nancy in history were not included in the regression
analyses as data were missing in, respectively, 56%, 72%,
54% (women only), and 49% (women only) of patients.
Characterization of patient undergoing invasive
therapy
Table S3 provides an overview of patient and disease
characteristics of individuals who underwent, respec-
tively, transplantation, resection, fenestration, and aspi-
ration sclerotherapy. Liver transplantation was carried
out at a median age of 53  10 years in a total of 77
patients of whom 69 were diagnosed with ADPKD. In
43% (n = 33) of patients, this was combined with a
renal transplantation and radiological imaging showed
a median TLV of 4271 ml [IQR 3438–6243 ml] in
these patients. Resection was carried out in six patients
(1%), and most patients underwent other treatment
modalities as well. Interestingly, a total of 27 patients
received >1 different treatment modality. A combina-
tion of fenestration and aspiration sclerotherapy was
most common (9%, n = 17). Only a small proportion
of the total study population underwent fenestration
(8%, n = 48), and a minority of them had ADPKD
(38%, n = 18). Patients who underwent fenestration or
Table 1. Characteristics of the study population.
Complete population
(n = 578)
Female 468 81%
ADPKD 383 66%
Age diagnosis PLD 45 13
Center 1 380 66%
Volumetry*
TLV (ml) 4093 [2717–6066]
hTLV (ml/m) 2639 [1669–3840]
Phenotype*
≥20 cysts + ≥1 dominant cyst 54 11%
≥20 cysts 421 89%
Symptoms
Abdominal tension 225 39%
Feeling full 210 36%
Abdominal pain 141 24%
Tiredness 129 22%
Pain rib cage 120 21%
Pain side 78 14%
No. of symptoms 1 [1–3]
ADPKD, autosomal dominant polycystic kidney disease; hTLV,
height-adjusted total liver volume; PLD, polycystic liver dis-
ease; TLV, total liver volume.
Date are in number and percentage (%), mean  standard
deviation, or median and interquartile range [IQR].
Center 1 = Radboud University Medical Center Nijmegen,
the Netherlands; center 2 = University Hospital of Leuven,
Belgium.
*Data were missing in, respectively, 56%, 72%, and 18% of
patients for TLV, hTLV, and phenotype.
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Figure 2 Liver cyst phenotype in patients with autosomal dominant
polycystic kidney disease (ADPKD) and autosomal dominant polycys-
tic liver disease (ADPLD). (a) A phenotype with dominant cysts
(≥8 cm) was significantly more present in ADPLD patients compared
with ADPKD patients (22% vs. 7%, P < 0.001). (b) A phenotype
without dominant cysts was more often present in ADPKD (93% vs.
78%, P < 0.001).
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aspiration sclerotherapy did not significantly differ on
sex, diagnosis, age at diagnosis, and phenotype
(Table S4). We found that the choice for fenestration
or aspiration sclerotherapy was mainly center depen-
dent (P < 0.001). Aspiration sclerotherapy was most
frequently performed with a total of 197 procedures in
100 patients. Half of patients (49%, n = 97) had >1
procedure (range 1–15 procedures), and the majority
of patients were diagnosed with ADPLD (65%,
n = 65).
Determinants associated with invasive therapies
We tested the association of six potential determinants
with the likelihood to undergo either liver transplanta-
tion, fenestration, or aspiration sclerotherapy (Fig. 3,
Table S5). Determinants associated with hepatic resec-
tion were not analyzed as only seven patients (1%)
underwent this procedure and a minimum of 10
patients was required. Patients from center 2 had a
30% higher likelihood (P < 0.001) to receive a liver
transplantation compared with patients from center 1
(Table S5). The likelihood to undergo a liver transplan-
tation increased by 4% with every 10 years of PLD
diagnosis (RR: 1.035, CI: 1.005–1.065). Multivariate
analysis revealed that a diagnosis of ADPLD increased
the likelihood to undergo fenestration by 30%
(P < 0.05). The number of symptoms was associated
with a higher likelihood to undergo aspiration scle-
rotherapy (RR: 1.1, P < 0.001). The likelihood to be
subjected to aspiration sclerotherapy was center depen-
dent (RR: 1.1, P = 0.03) and increased by follow-up
time (RR = 1.1, P = 0.002).
Therapy differs between patients with ADPKD and
ADPLD
We subsequently explored whether treatment strategies
differed between patients with ADPKD and ADPLD.
Fenestration and aspiration sclerotherapy was signifi-
cantly more often performed in patients with ADPLD
than in patients with ADPKD (15% vs. 5% and 33% vs.
9%, both P < 0.001) (Fig. 4). By contrast, patients with
ADPKD more frequently underwent liver
0.6 0.8 1.0 1.2 1.4
Center 
No of symptoms
Follow-up
Aspiration sclerotherapy
0 1 2 3
No of symptoms
Age PLD diagnosis
Follow-up
Treatment overall
0.6 0.8 1.0
Center 
Age PLD diagnosis
Liver transplantation
0.0 0.5 1.0 1.5 2.0
ADPLD diagnosis
Fenestration
Figure 3 Forest plots showing risk
ratios with 95% confidence intervals
for, respectively, treatment in
general, liver transplantation,
fenestration, and aspiration
sclerotherapy. Risk ratios were
calculated by multivariate regression
analyses. A risk ratio of <1 represents
a decreased risk and >1 increased risk
for treatment. A risk ratio of 1
(dotted line) indicates no association.
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Figure 4 Treatment strategies for polycystic liver disease (PLD) in
autosomal dominant polycystic kidney disease (ADPKD) and autoso-
mal dominant polycystic liver disease (ADPLD). Liver transplantation
was more often carried out in patients with ADPKD whereas fenes-
tration and aspiration sclerotherapy favored patients with ADPLD.
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transplantation (18% vs. 4%, P < 0.001). In a total of
33 patients undergoing liver transplantation, this was
combined with a renal transplantation on the same day.
Discussion
The results of our large cross-sectional study demon-
strate that number of symptoms and age at diagnosis of
PLD increased the likelihood to receive treatment for
PLD. The choice for either liver transplantation or aspi-
ration sclerotherapy was center dependent. This under-
scores a certain arbitrariness, probably due to a lack of
evidence that supports any of the available treatment
options.
A previous review suggests that the natural course of
PLD in ADPLD and ADPKD is similar [3]. Our study
suggests otherwise and demonstrates that patients with
ADPLD more often possessed large dominant cysts, a
phenotype that is amendable to treatment with fenestra-
tion or aspiration sclerotherapy [3]. The available thera-
pies for patients without dominant cysts, most often
patients with ADPKD, are resection or liver transplanta-
tion [2,3]. A resection is a high-risk procedure and not
often performed in our population. Liver transplanta-
tion is a very invasive procedure, in particular for a dis-
ease that does not lead to liver failure or death. In view
of a lack of donors, it is not offered widely [2,3]. These
reasons probably explain why only 13% of this severe
PLD population was transplanted while a higher per-
centage is in need of curative therapy. Interestingly,
90% of the transplanted patients were female. This
might be explained by a more severe disease course in
women, probably due to the effect of estrogen [9].
However, diagnosis was not significantly associated with
any of the invasive therapies. These results are in con-
tradiction with a cohort study showing that aspiration
sclerotherapy was significantly more performed in
patients with ADPLD, while patients with ADPKD were
more often considered for liver transplantation [19].
About 14% of our treated study population under-
went subsequent treatments. The combination of fenes-
tration and aspiration sclerotherapy was the most
frequently chosen option. In view of the comparable
patients’ characteristics, our data lend support to cen-
ter-specific decision-making when it comes to the
choice between both treatment modalities. These find-
ings indicate that available expertise drives treatment
while evidence that singles out the best treatment
modality is lacking. A randomized controlled trial com-
paring effectiveness of fenestration and aspiration scle-
rotherapy is necessary to find out which treatment
strategy is most effective. At the minimum, we should
assess treatment outcomes in clinical care of PLD in an
uniform fashion. Assessment of TLV, symptoms, and
health-related quality of life before and after treatment
should become standard of care and collected in a reg-
istry to build an evidence base of treatment efficacy
[13]. In addition, our results demonstrated that liver
transplantation was more frequently performed in Bel-
gium while in the Netherlands there was a preference
for aspiration sclerotherapy. Due to a different organ
donor policy, Belgium has more donors available. This
might lower the threshold for physicians to offer trans-
plantation as a treatment option.
Our study also discovered that a large proportion of
patients received treatment (35%), which is at odds with
the literature that indicates that only a small subset of
patients is symptomatic [2,3,11]. Our population con-
sists of patients referred to two nationwide tertiary refer-
ral centers, which may have contributed to a selection of
a population with more severe disease. This may overes-
timate the disease burden of PLD in this population as
referral to these centers is often triggered by presence of
symptoms. The threshold to treat patients with PLD is
probably lower in tertiary centers because of wider expe-
rience with PLD and its treatment options.
The strength of our study was the large, international
study population (n = 578) in view of the rarity of PLD.
In addition, both patients with ADPKD and ADPLD
were represented in this study as well as the most preva-
lent surgical therapies. Patients from all over the country
are referred to one of both centers, and therefore, this
study provides a good overview of the clinical profile of
treated patients in both countries and made it possible
to study the effect of center on treatment decision.
The main limitation of our study is the cross-sec-
tional design. We were able to investigate factors
involved in treatment decision, but it is impossible to
infer causality. The retrospective data collection has led
to missing data and therefore liver volume could not be
included as potential determinant in our prediction
model. Assessment of liver volume is time consuming,
and trained staff and software are required. This might
explain the amount of missing data for TLV. Although,
it is questionable whether liver volume plays a major
role in the treatment decision process as so little vol-
umes were available in the medical charts. Therefore,
this probably had no major impact on the primary out-
come. This registry will continue in a prospective fash-
ion including more patients worldwide with a long-
term follow-up. A prospective nature will decrease the
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number of missing data, and the long-term follow-up
will support to learn more about the prognosis of PLD.
Conclusion
The results of our international cross-sectional study sug-
gest that a higher number of symptoms and every 10 years
of PLD diagnosis increase the likelihood to undergo treat-
ment by 40%. The choice to elect a particular modality is
center dependent. The major implication of these findings
is that physicians should bear in mind that there is no evi-
dence that favors either treatment option, and this con-
tributes to center-specific preferences. Therefore, assessing
efficacy of therapy by measuring liver volume and symp-
tom burden is essential to gain evidence among the best
treatment option. Future studies comparing efficacy of
treatment modalities would be helpful to fill the gap of
knowledge among the best treatment options.
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